Patent estate

SUMITOMO PHARMA AM — Patent Portfolio

1 drug with active patents · 20 active patents · 8 expired · 0 biologics with BPCIA exclusivity

AI-enriched 20/20 patents with grounded plain-English summaries · sourced from FDA Orange Book + Purple Book · updated 2026-05-18

§
Strategic Patent Estate Brief
AI-grounded executive summary · generated 2026-05-16

Verdict The SUMITOMO PHARMA AM portfolio is moderately strong, with a significant cliff year in 2028 and no revenue at risk in the next 5 years.

Portfolio overview The SUMITOMO PHARMA AM portfolio consists of a total of 2 drugs, with 1 of them having patents. The company has a total of 28 US patents, with 20 active and 8 expired. The average vulnerability score is 50, indicating a moderate level of vulnerability. The patent estate is split between 4 ironclad patents and 4 vulnerable patents. Notably, the company has no biologics with BPCIA exclusivity.

Cliff calendar 5 drugs lose exclusivity in 2028 including Aptiom. This year will be a significant cliff year for the company, with Aptiom being one of the key drugs losing exclusivity.

Most exposed drugs Aptiom is the top drug facing near-term loss of exclusivity, with an earliest active patent expiry date of 2028-09-13 and an average vulnerability score of 60. Unfortunately, the annual revenue for Aptiom is not available.

Biologic exclusivity The SUMITOMO PHARMA AM portfolio does not have any biologics with BPCIA exclusivity.

Strategic implications The company has no revenue at risk in the next 5 years. However, the loss of exclusivity for Aptiom in 2028 will require the company to consider lifecycle moves such as subQ switches, label extensions, or combination filings to maintain revenue.

Sources: FDA Orange Book · FDA Purple Book · INPADOC family · USPTO · vulnerability scoring. Not legal advice.

Loss of exclusivity calendar · next 12 years

Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.

1 2028 1 2030 1 2032

Patent estate by drug

Aptiom (ESLICARBAZEPINE ACETATE)

Cliff 2028 · 2y
Method of Use 8 Formulation 12
  • US9763954 Vuln 75 2028-09-13
    This patent protects new therapeutic uses of eslicarbazepine and eslicarbazepine acetate for treating intractable conditions.
  • US9763954 Vuln 75 2028-09-13
    This patent protects new therapeutic uses of eslicarbazepine and eslicarbazepine acetate for treating intractable conditions.
  • US9763954 Vuln 75 2028-09-13
    This patent protects new therapeutic uses of eslicarbazepine and eslicarbazepine acetate for treating intractable conditions.
See all 20 patents →

Patent classification breakdown · active patents

By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.

  • Formulation 12 patents
  • Method of Use 8 patents

Sources

  • FDA Orange Book — small-molecule patents listed against approved NDAs.
  • FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
  • USPTO Patent Public Search — title, abstract, claim text grounding.
  • AI summaries generated by Drug Landscape, grounded in source claim text.

Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.

Track SUMITOMO PHARMA AM's patent estate

Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.

↓ CSV export